Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.83 |
| ▸ | MMP10 | P09238 | 5/20 | 0.68 |
| ▸ | MMP8 | P22894 | 5/20 | 0.68 |
| ▸ | MMP9 | P14780 | 1/20 | 0.68 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838134 | 0.91 | MMP13 (1.00) | MMP13MMP10MMP8MMP9HCRTR1 | |
| SCHEMBL8358823 | 0.91 | MMP13 (1.00) | MMP13MMP10MMP8MMP9HCRTR1 | |
| SCHEMBL4716566 | 0.89 | MMP13 (0.90) | MMP13MMP10MMP8MMP9HCRTR1 | |
| SCHEMBL8360162 | 0.88 | MMP13 (0.88) | MMP13MMP10MMP8MMP9HCRTR1 | |
| SCHEMBL12272887 | 0.88 | MMP13 (0.92) | MMP13MMP10MMP8MMP9HCRTR1 | |
| SCHEMBL14284143 | 0.86 | MMP13 (0.90) | MMP13MMP10MMP8MMP9HCRTR1 | |
| SCHEMBL8357428 | 0.86 | MMP13 (0.90) | MMP13MMP10MMP8MMP9L3MBTL1 | |
| SCHEMBL5615671 | 0.86 | MMP13 (0.84) | MMP13MMP10MMP8MMP9HCRTR1 | |
| SCHEMBL15647278 | 0.86 | MMP13 (0.86) | MMP13MMP10MMP8MMP9 | |
| SCHEMBL14284169 | 0.85 | MMP13 (0.83) | MMP13MMP10MMP8MMP9HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | MMP13 11/4885MMP10 8/4885MMP8 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.